{"transactions":[{"id":4631316,"issuer":{"id":7026,"kind":"organization","name":"Outset Medical, Inc.","symbol":"OM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-05T23:24:40.000Z","date":"2026-10-02","kind":"purchase","planned":false,"acquired":true,"shares":16575,"price":3.8758,"value":64241.385,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were purchased in multiple transactions at an average price of $3.8758 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2764610,"source":{"system":"sec-edgar","filing":"0001373604-26-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1484612/000137360426000050/form4.xml","form_type":"4"}},{"id":4631315,"issuer":{"id":7026,"kind":"organization","name":"Outset Medical, Inc.","symbol":"OM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-05T23:24:40.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":228334,"price":3.53,"value":806019.02,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were purchased in multiple transactions between $2.90 and $3.85 with an average price of $3.53."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2748035,"source":{"system":"sec-edgar","filing":"0001373604-26-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484612/000137360426000050/form4.xml","form_type":"4"}},{"id":774954,"issuer":{"id":7026,"kind":"organization","name":"Outset Medical, Inc.","symbol":"OM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-05-18T13:53:35.000Z","date":"2026-05-15","kind":"other","planned":false,"acquired":true,"shares":323000,"price":5,"value":1615000.0,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting owner was short June, 2026 put options and these shares were assigned on expiration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2519701,"source":{"system":"sec-edgar","filing":"0001373604-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484612/000137360426000043/form4.xml","form_type":"4"}},{"id":782290,"issuer":{"id":7026,"kind":"organization","name":"Outset Medical, Inc.","symbol":"OM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-05-12T20:34:17.000Z","date":"2026-05-11","kind":"other","planned":false,"acquired":true,"shares":96900,"price":5,"value":484500.0,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2196701,"source":{"system":"sec-edgar","filing":"0001373604-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1484612/000137360426000036/form4.xml","form_type":"4"}},{"id":782289,"issuer":{"id":7026,"kind":"organization","name":"Outset Medical, Inc.","symbol":"OM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-05-12T20:34:17.000Z","date":"2026-05-08","kind":"other","planned":false,"acquired":true,"shares":197600,"price":5,"value":988000.0,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2099801,"source":{"system":"sec-edgar","filing":"0001373604-26-000036","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484612/000137360426000036/form4.xml","form_type":"4"}},{"id":799968,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2026-04-27T23:27:01.000Z","date":"2026-04-23","kind":"sale","planned":false,"acquired":false,"shares":300000,"price":4.53,"value":1359000.0,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13950000,"source":{"system":"sec-edgar","filing":"0001373604-26-000034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360426000034/form4.xml","form_type":"4"}},{"id":978808,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-12-05T23:20:04.000Z","date":"2025-12-04","kind":"sale","planned":false,"acquired":false,"shares":524560,"price":4.1947,"value":2200371.832,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares sold in multiple transactions at a price of $4.1947 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1958080,"source":{"system":"sec-edgar","filing":"0001373604-25-000122","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000122/form4.xml","form_type":"4"}},{"id":981230,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-12-04T02:39:32.000Z","date":"2025-12-03","kind":"sale","planned":false,"acquired":false,"shares":222925,"price":4.17,"value":929597.25,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares sold in multiple transactions at a price of $4.17 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2428640,"source":{"system":"sec-edgar","filing":"0001373604-25-000118","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000118/form4.xml","form_type":"4"}},{"id":981229,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-12-04T02:39:32.000Z","date":"2025-12-02","kind":"sale","planned":false,"acquired":false,"shares":51961,"price":4.2,"value":218236.2,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares sold in multiple transactions at a price of $4.20 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2705565,"source":{"system":"sec-edgar","filing":"0001373604-25-000118","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000118/form4.xml","form_type":"4"}},{"id":981228,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-12-04T02:39:32.000Z","date":"2025-12-01","kind":"sale","planned":false,"acquired":false,"shares":300000,"price":4.2,"value":1260000.0,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares sold in multiple transactions at a price of $4.20 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2757526,"source":{"system":"sec-edgar","filing":"0001373604-25-000118","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000118/form4.xml","form_type":"4"}},{"id":1022570,"issuer":{"id":7805,"kind":"organization","name":"ASTROTECH Corp","symbol":"ASTC"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-10-08T00:51:19.000Z","date":"2025-10-03","kind":"sale","planned":false,"acquired":false,"shares":9166,"price":5.83,"value":53437.78,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001373604-25-000106","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1001907/000137360425000106/form4.xml","form_type":"4"}},{"id":1022569,"issuer":{"id":7805,"kind":"organization","name":"ASTROTECH Corp","symbol":"ASTC"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-10-08T00:51:19.000Z","date":"2025-10-03","kind":"sale","planned":false,"acquired":false,"shares":220410,"price":7.1305,"value":1571633.505,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at an average price of $7.1305."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001373604-25-000106","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001907/000137360425000106/form4.xml","form_type":"4"}},{"id":1109982,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-06-16T19:40:59.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":1.09,"value":218000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3017432,"source":{"system":"sec-edgar","filing":"0001373604-25-000090","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000137360425000090/form4.xml","form_type":"4"}},{"id":1129396,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-05-30T21:40:38.000Z","date":"2025-05-30","kind":"sale","planned":false,"acquired":false,"shares":7000,"price":1.0324,"value":7226.8,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at an average price of $1.0324."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3217432,"source":{"system":"sec-edgar","filing":"0001373604-25-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000137360425000084/form4.xml","form_type":"4"}},{"id":1129395,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-05-30T21:40:38.000Z","date":"2025-05-30","kind":"sale","planned":false,"acquired":false,"shares":425000,"price":1.01,"value":429250.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3224432,"source":{"system":"sec-edgar","filing":"0001373604-25-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000137360425000084/form4.xml","form_type":"4"}},{"id":1129394,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-05-30T21:40:38.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":1.16,"value":116000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3649432,"source":{"system":"sec-edgar","filing":"0001373604-25-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000137360425000084/form4.xml","form_type":"4"}},{"id":1129393,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-05-30T21:40:38.000Z","date":"2025-05-28","kind":"sale","planned":false,"acquired":false,"shares":2000000,"price":1.16,"value":2320000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3749432,"source":{"system":"sec-edgar","filing":"0001373604-25-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000137360425000084/form4.xml","form_type":"4"}},{"id":1164773,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-28T19:31:52.000Z","date":"2025-03-27","kind":"purchase","planned":false,"acquired":true,"shares":16593,"price":5.1883,"value":86089.4619,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.1883 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range"},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"This amendment is being filed to correct BOX 4 on the transaction date of 3/27/25 to correct a clerical error.  BOX 4 has been amended to \"A\", as the shares were acquired, not disposed."}],"balance_after":141800,"source":{"system":"sec-edgar","filing":"0001373604-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000069/form4.xml","form_type":"4/A","original_submission_date":"2025-03-27"}},{"id":1164772,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-28T19:31:52.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":20407,"price":5.0395,"value":102841.0765,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.0395 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range."}],"balance_after":125207,"source":{"system":"sec-edgar","filing":"0001373604-25-000069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000069/form4.xml","form_type":"4/A","original_submission_date":"2025-03-27"}},{"id":1164771,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-28T19:24:13.000Z","date":"2025-03-27","kind":"purchase","planned":false,"acquired":true,"shares":16593,"price":5.1883,"value":86089.4619,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.1883 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range"},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"This amendment is being filed to correct BOX 4 on the transaction date of 3/27/25 to correct a clerical error.  BOX 4 has been amended to \"A\", as the shares were acquired, not disposed."}],"balance_after":141800,"source":{"system":"sec-edgar","filing":"0001373604-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000067/form4.xml","form_type":"4"}},{"id":1164770,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-28T19:24:13.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":20407,"price":5.0395,"value":102841.0765,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.0395 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range."}],"balance_after":125207,"source":{"system":"sec-edgar","filing":"0001373604-25-000067","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000067/form4.xml","form_type":"4"}},{"id":1166256,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-24T13:35:07.000Z","date":"2025-04-23","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":2.979,"value":148950.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $2.979 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range."}],"balance_after":191800,"source":{"system":"sec-edgar","filing":"0001373604-25-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000065/form4.xml","form_type":"4"}},{"id":1166255,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-24T13:35:07.000Z","date":"2025-04-22","kind":"purchase","planned":false,"acquired":true,"shares":300000,"price":3,"value":900000.0,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3057526,"source":{"system":"sec-edgar","filing":"0001373604-25-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000065/form4.xml","form_type":"4"}},{"id":1182813,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-02T22:07:02.000Z","date":"2025-04-02","kind":"purchase","planned":false,"acquired":true,"shares":15209,"price":4.0376,"value":61407.8584,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.0376 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2757526,"source":{"system":"sec-edgar","filing":"0001373604-25-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000058/form4.xml","form_type":"4"}},{"id":1182812,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-02T22:07:02.000Z","date":"2025-03-31","kind":"purchase","planned":false,"acquired":true,"shares":19566,"price":4.3784,"value":85667.7744,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.3784 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2742317,"source":{"system":"sec-edgar","filing":"0001373604-25-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000058/form4.xml","form_type":"4"}},{"id":1189548,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-03-27T23:06:28.000Z","date":"2025-03-27","kind":"purchase","planned":false,"acquired":false,"shares":16593,"price":5.1883,"value":86089.4619,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.1883 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range"}],"balance_after":141800,"source":{"system":"sec-edgar","filing":"0001373604-25-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000056/form4.xml","form_type":"4"}},{"id":1189547,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-03-27T23:06:28.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":20407,"price":5.0395,"value":102841.0765,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.0395 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range."}],"balance_after":125207,"source":{"system":"sec-edgar","filing":"0001373604-25-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000056/form4.xml","form_type":"4"}},{"id":1195481,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stovk","published_at":"2025-03-21T00:02:25.000Z","date":"2025-03-20","kind":"purchase","planned":false,"acquired":true,"shares":30600,"price":5.6133,"value":171766.98,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $5.6074 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2722761,"source":{"system":"sec-edgar","filing":"0001373604-25-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000051/form4.xml","form_type":"4"}},{"id":1195480,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-03-21T00:02:25.000Z","date":"2025-03-19","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":4.9356,"value":123390.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.9356per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2692161,"source":{"system":"sec-edgar","filing":"0001373604-25-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000051/form4.xml","form_type":"4"}},{"id":1195479,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-03-21T00:02:25.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":44341,"price":4.7274,"value":209617.6434,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.7274 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2667161,"source":{"system":"sec-edgar","filing":"0001373604-25-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000051/form4.xml","form_type":"4"}},{"id":1195478,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-03-21T00:02:25.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":18000,"price":4.6,"value":82800.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2622820,"source":{"system":"sec-edgar","filing":"0001373604-25-000051","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000051/form4.xml","form_type":"4"}},{"id":1238076,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-02-28T21:04:36.000Z","date":"2025-02-28","kind":"purchase","planned":false,"acquired":true,"shares":85068,"price":4.5965,"value":391015.062,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.5965per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2604820,"source":{"system":"sec-edgar","filing":"0001373604-25-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000041/form4.xml","form_type":"4"}},{"id":1238075,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-02-28T21:04:36.000Z","date":"2025-02-27","kind":"purchase","planned":false,"acquired":true,"shares":86802,"price":4.4595,"value":387093.519,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.4595 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2519752,"source":{"system":"sec-edgar","filing":"0001373604-25-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000041/form4.xml","form_type":"4"}},{"id":1238074,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-02-28T21:04:36.000Z","date":"2025-02-26","kind":"purchase","planned":false,"acquired":true,"shares":164886,"price":4.0087,"value":660978.5082,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $4.0087 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2432950,"source":{"system":"sec-edgar","filing":"0001373604-25-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360425000041/form4.xml","form_type":"4"}},{"id":1388525,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"other":true,"other_text":"Former 10% owner of RPHM"}}],"security":"Common Stock","published_at":"2024-10-09T15:25:07.000Z","date":"2024-10-07","kind":"other","planned":false,"acquired":true,"shares":102076,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 1,020,769 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10.  On October 4, 2024 (the \"Closing Date\"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company (\"Reneo\"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub I\"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub II\"), and OnKure, Inc., a Delaware corporation (\"Legacy OnKure\")."}],"balance_after":102076,"source":{"system":"sec-edgar","filing":"0001373604-24-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000100/form4.xml","form_type":"4"}},{"id":1388524,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"other":true,"other_text":"Former 10% owner of RPHM"}}],"security":"Common Stock","published_at":"2024-10-09T15:25:07.000Z","date":"2024-10-07","kind":"other","planned":false,"acquired":true,"shares":345739,"ownership":{"direct":false,"nature":"Holdings of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 3,457,395 shares of common stock of Reneo Pharmaceuticals. Pursuant to the Merger Agreement, on the Closing Date, Reneo effected a reverse stock split of Reneo's issued common stock at a ratio of 1:10.  On October 4, 2024 (the \"Closing Date\"), Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company (\"Reneo\"), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub I\"), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Reneo (\"Merger Sub II\"), and OnKure, Inc., a Delaware corporation (\"Legacy OnKure\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":345739,"source":{"system":"sec-edgar","filing":"0001373604-24-000100","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000100/form4.xml","form_type":"4"}},{"id":1398886,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-26T13:33:44.000Z","date":"2024-09-25","kind":"purchase","planned":false,"acquired":true,"shares":68746,"price":1.4964,"value":102871.5144,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchased in multiple transactions with a weighted average price of $1.4964. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3457395,"source":{"system":"sec-edgar","filing":"0001373604-24-000098","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000098/form4.xml","form_type":"4"}},{"id":1398885,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-26T13:33:44.000Z","date":"2024-09-24","kind":"purchase","planned":false,"acquired":true,"shares":29600,"price":1.4144,"value":41866.24,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in multiple transactions with a weighted average price of $1.4144. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3388649,"source":{"system":"sec-edgar","filing":"0001373604-24-000098","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000098/form4.xml","form_type":"4"}},{"id":1402202,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-19T15:02:54.000Z","date":"2024-09-18","kind":"purchase","planned":false,"acquired":true,"shares":806,"price":1.4,"value":1128.4,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchased in multiple transactions with a weighted average price of $1.40. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3359049,"source":{"system":"sec-edgar","filing":"0001373604-24-000094","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000094/form4.xml","form_type":"4"}},{"id":1402201,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-19T15:02:54.000Z","date":"2024-09-17","kind":"purchase","planned":false,"acquired":true,"shares":55300,"price":1.3582,"value":75108.46,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in multiple transactions with a weighted average price of $1.3582. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3358243,"source":{"system":"sec-edgar","filing":"0001373604-24-000094","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000094/form4.xml","form_type":"4"}},{"id":1406452,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-16T20:15:23.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":172747,"price":1.3712,"value":236870.6864,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Purchased in multiple transactions with a weighted average price of $1.3712. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3302943,"source":{"system":"sec-edgar","filing":"0001373604-24-000090","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000090/form4.xml","form_type":"4"}},{"id":1406451,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-16T20:15:23.000Z","date":"2024-09-13","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":1.313,"value":196950.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchased in multiple transactions with a weighted average price of $1.313. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3130196,"source":{"system":"sec-edgar","filing":"0001373604-24-000090","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000090/form4.xml","form_type":"4"}},{"id":1406450,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-16T20:15:23.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":36176,"price":1.3966,"value":50523.4016,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in multiple transactions with a weighted average price of $1.3966. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2980196,"source":{"system":"sec-edgar","filing":"0001373604-24-000090","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000090/form4.xml","form_type":"4"}},{"id":1411723,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-09T20:24:12.000Z","date":"2024-09-06","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.484,"value":37100.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":248702,"source":{"system":"sec-edgar","filing":"0001373604-24-000088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000088/form4.xml","form_type":"4"}},{"id":1411722,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-09T20:24:12.000Z","date":"2024-09-05","kind":"purchase","planned":false,"acquired":true,"shares":5100,"price":1.4,"value":7140.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":223702,"source":{"system":"sec-edgar","filing":"0001373604-24-000088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000088/form4.xml","form_type":"4"}},{"id":1413615,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-05T15:57:28.000Z","date":"2024-09-03","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":4,"value":2000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":218602,"source":{"system":"sec-edgar","filing":"0001373604-24-000086","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000086/form4.xml","form_type":"4"}},{"id":1415344,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-05T00:19:50.000Z","date":"2024-08-30","kind":"purchase","planned":false,"acquired":true,"shares":151,"price":4.25,"value":641.75,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":218602,"source":{"system":"sec-edgar","filing":"0001373604-24-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000084/form4.xml","form_type":"4"}},{"id":1420636,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-28T20:45:05.000Z","date":"2024-08-28","kind":"purchase","planned":false,"acquired":true,"shares":1215,"price":3.9627,"value":4814.6805,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":217951,"source":{"system":"sec-edgar","filing":"0001373604-24-000081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000081/form4.xml","form_type":"4"}},{"id":1420635,"issuer":{"id":87664,"kind":"organization","name":"Talis Biomedical Corp","symbol":"TLIS"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-28T20:45:05.000Z","date":"2024-08-26","kind":"purchase","planned":false,"acquired":true,"shares":13167,"price":3.8978,"value":51322.3326,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":216736,"source":{"system":"sec-edgar","filing":"0001373604-24-000081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000081/form4.xml","form_type":"4"}},{"id":1433423,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-15T00:48:16.000Z","date":"2024-08-14","kind":"purchase","planned":false,"acquired":true,"shares":100487,"price":1.4132,"value":142008.2284,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchased in multiple transactions with a weighted average price of $1.4132. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2944020,"source":{"system":"sec-edgar","filing":"0001373604-24-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000071/form4.xml","form_type":"4"}},{"id":1433422,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-15T00:48:16.000Z","date":"2024-08-13","kind":"purchase","planned":false,"acquired":true,"shares":171339,"price":1.3925,"value":238589.5575,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in multiple transactions with a weighted average price of $1.3925. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2843533,"source":{"system":"sec-edgar","filing":"0001373604-24-000071","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000071/form4.xml","form_type":"4"}},{"id":1433884,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-15T00:24:00.000Z","date":"2024-08-14","kind":"purchase","planned":false,"acquired":true,"shares":1500000,"price":1.04,"value":1560000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":5749432,"source":{"system":"sec-edgar","filing":"0001373604-24-000066","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000137360424000066/form4.xml","form_type":"4"}},{"id":1440497,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-05T19:57:34.000Z","date":"2024-08-05","kind":"purchase","planned":false,"acquired":true,"shares":206025,"price":1.2443,"value":256356.9075,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.2443 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":14250000,"source":{"system":"sec-edgar","filing":"0001373604-24-000060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000060/form4.xml","form_type":"4"}},{"id":1440496,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-05T19:57:34.000Z","date":"2024-08-02","kind":"purchase","planned":false,"acquired":true,"shares":167544,"price":1.2916,"value":216399.8304,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.2916 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":14043975,"source":{"system":"sec-edgar","filing":"0001373604-24-000060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000060/form4.xml","form_type":"4"}},{"id":1445154,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-31T20:19:29.000Z","date":"2024-07-30","kind":"purchase","planned":false,"acquired":true,"shares":85800,"price":7.15,"value":613470.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2268064,"source":{"system":"sec-edgar","filing":"0001373604-24-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000058/form4.xml","form_type":"4"}},{"id":1445153,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-31T20:10:09.000Z","date":"2024-07-31","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.3264,"value":132640.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.3264 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13876421,"source":{"system":"sec-edgar","filing":"0001373604-24-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000056/form4.xml","form_type":"4"}},{"id":1445152,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-31T20:10:09.000Z","date":"2024-07-30","kind":"purchase","planned":false,"acquired":true,"shares":173730,"price":1.303,"value":226370.19,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.303 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13776421,"source":{"system":"sec-edgar","filing":"0001373604-24-000056","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000056/form4.xml","form_type":"4"}},{"id":1450370,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:03:02.000Z","date":"2024-07-22","kind":"purchase","planned":false,"acquired":true,"shares":17716,"price":1.3297,"value":23556.9652,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.3297per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13602691,"source":{"system":"sec-edgar","filing":"0001373604-24-000052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000052/form4.xml","form_type":"4"}},{"id":1450369,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:03:02.000Z","date":"2024-07-19","kind":"purchase","planned":false,"acquired":true,"shares":6689,"price":1.3,"value":8695.7,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.30 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13584975,"source":{"system":"sec-edgar","filing":"0001373604-24-000052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000052/form4.xml","form_type":"4"}},{"id":1450368,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-22T20:03:02.000Z","date":"2024-07-18","kind":"purchase","planned":false,"acquired":true,"shares":130317,"price":1.3011,"value":169555.4487,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.3011 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13578286,"source":{"system":"sec-edgar","filing":"0001373604-24-000052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000052/form4.xml","form_type":"4"}},{"id":1451702,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-19T01:16:05.000Z","date":"2024-07-18","kind":"purchase","planned":false,"acquired":true,"shares":80718,"price":9.1149,"value":735736.4982,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $9.114 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2182264,"source":{"system":"sec-edgar","filing":"0001373604-24-000049","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000049/form4.xml","form_type":"4"}},{"id":1451701,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-19T01:16:05.000Z","date":"2024-07-17","kind":"purchase","planned":false,"acquired":true,"shares":135546,"price":7.7459,"value":1049925.7614,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $7.7459 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2101546,"source":{"system":"sec-edgar","filing":"0001373604-24-000049","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000049/form4.xml","form_type":"4"}},{"id":1458753,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-05T18:46:52.000Z","date":"2024-07-05","kind":"purchase","planned":false,"acquired":true,"shares":123017,"price":1.1489,"value":141334.2313,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1489per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13447969,"source":{"system":"sec-edgar","filing":"0001373604-24-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000045/form4.xml","form_type":"4"}},{"id":1458752,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-05T18:46:52.000Z","date":"2024-07-03","kind":"purchase","planned":false,"acquired":true,"shares":143288,"price":1.159,"value":166070.792,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.159 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13324952,"source":{"system":"sec-edgar","filing":"0001373604-24-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000045/form4.xml","form_type":"4"}},{"id":1458751,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-05T18:46:52.000Z","date":"2024-07-02","kind":"purchase","planned":false,"acquired":true,"shares":86092,"price":1.144,"value":98489.248,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.144 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13181664,"source":{"system":"sec-edgar","filing":"0001373604-24-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000045/form4.xml","form_type":"4"}},{"id":1465548,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-01T17:39:08.000Z","date":"2024-07-01","kind":"purchase","planned":false,"acquired":true,"shares":107434,"price":1.1373,"value":122184.6882,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1373per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":13095572,"source":{"system":"sec-edgar","filing":"0001373604-24-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000042/form4.xml","form_type":"4"}},{"id":1465547,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-01T17:39:08.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":1.13,"value":452000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":12988134,"source":{"system":"sec-edgar","filing":"0001373604-24-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000042/form4.xml","form_type":"4"}},{"id":1465546,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-01T17:39:08.000Z","date":"2024-06-28","kind":"purchase","planned":false,"acquired":true,"shares":801000,"price":1.1193,"value":896559.3,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1193 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":12588134,"source":{"system":"sec-edgar","filing":"0001373604-24-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000042/form4.xml","form_type":"4"}},{"id":1465545,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-01T17:39:08.000Z","date":"2024-06-27","kind":"purchase","planned":false,"acquired":true,"shares":235000,"price":1.1546,"value":271331.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1546 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":11787134,"source":{"system":"sec-edgar","filing":"0001373604-24-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000042/form4.xml","form_type":"4"}},{"id":1469363,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"other":true,"other_text":"Former 10% owner of AVROBIO"}}],"security":"Common Stock","published_at":"2024-06-25T17:42:11.000Z","date":"2024-06-20","kind":"other","planned":false,"acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 400,000 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the \"Merger Agreement\") by and among AVROBIO, Inc., a Delaware corporation (\"AVROBIO\"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the \"Merger Sub\"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the \"Merger\"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc."}],"balance_after":33333,"source":{"system":"sec-edgar","filing":"0001373604-24-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000039/form4.xml","form_type":"4"}},{"id":1469362,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"other":true,"other_text":"Former 10% owner of AVROBIO"}}],"security":"Common Stock","published_at":"2024-06-25T17:42:11.000Z","date":"2024-06-20","kind":"other","planned":false,"acquired":true,"shares":400355,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P,"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 4,768,262 shares of common stock of AVROBIO, Inc., pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the \"Merger Agreement\") by and among AVROBIO, Inc., a Delaware corporation (\"AVROBIO\"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the \"Merger Sub\"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the \"Merger\"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of AVROBIO common stock reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":400355,"source":{"system":"sec-edgar","filing":"0001373604-24-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000039/form4.xml","form_type":"4"}},{"id":1474778,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-18T20:04:29.000Z","date":"2024-06-18","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.1301,"value":56505.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1301per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":11552134,"source":{"system":"sec-edgar","filing":"0001373604-24-000037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000037/form4.xml","form_type":"4"}},{"id":1474777,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-18T20:04:29.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":1.13,"value":169500.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.13 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":11502134,"source":{"system":"sec-edgar","filing":"0001373604-24-000037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000037/form4.xml","form_type":"4"}},{"id":1474776,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-18T20:04:29.000Z","date":"2024-06-14","kind":"purchase","planned":false,"acquired":true,"shares":345000,"price":1.1658,"value":402201.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1658 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":11352134,"source":{"system":"sec-edgar","filing":"0001373604-24-000037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000037/form4.xml","form_type":"4"}},{"id":1480299,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-13T22:04:27.000Z","date":"2024-06-13","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":1.15,"value":575000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":11007134,"source":{"system":"sec-edgar","filing":"0001373604-24-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000035/form4.xml","form_type":"4"}},{"id":1480298,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-13T22:04:27.000Z","date":"2024-06-13","kind":"purchase","planned":false,"acquired":true,"shares":28621,"price":1.1445,"value":32756.7345,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.1445 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":10507134,"source":{"system":"sec-edgar","filing":"0001373604-24-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000035/form4.xml","form_type":"4"}},{"id":1480297,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-13T22:04:27.000Z","date":"2024-06-12","kind":"purchase","planned":false,"acquired":true,"shares":82579,"price":1.14,"value":94140.06,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $1.14 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":10478513,"source":{"system":"sec-edgar","filing":"0001373604-24-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000035/form4.xml","form_type":"4"}},{"id":1480296,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-13T22:04:27.000Z","date":"2024-06-11","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":1.08,"value":1080000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":10395934,"source":{"system":"sec-edgar","filing":"0001373604-24-000035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000035/form4.xml","form_type":"4"}},{"id":1513917,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-16T12:58:26.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":335000,"price":1.54,"value":515900.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchased in multiple transactions with a weighted average price of $1.54. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2672194,"source":{"system":"sec-edgar","filing":"0001373604-24-000028","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000028/form4.xml","form_type":"4"}},{"id":1513916,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-16T12:58:26.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":79281,"price":1.56,"value":123678.36,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in multiple transactions with a weighted average price of $1.56. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":2337194,"source":{"system":"sec-edgar","filing":"0001373604-24-000028","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000028/form4.xml","form_type":"4"}},{"id":1515691,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-15T15:21:34.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":296882,"price":1.3,"value":385946.6,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Purchased in multiple transactions with a weighted average price of $1.30.  The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":4768262,"source":{"system":"sec-edgar","filing":"0001373604-24-000022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000022/form4.xml","form_type":"4"}},{"id":1515690,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-15T15:21:34.000Z","date":"2024-05-13","kind":"purchase","planned":false,"acquired":true,"shares":216053,"price":1.26,"value":272226.78,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchased in multiple transactions with an weighted average price of $1.26.  The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":4471380,"source":{"system":"sec-edgar","filing":"0001373604-24-000022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000022/form4.xml","form_type":"4"}},{"id":1515689,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-15T15:21:34.000Z","date":"2024-05-13","kind":"purchase","planned":false,"acquired":true,"shares":253700,"price":1.235,"value":313319.5,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":4255327,"source":{"system":"sec-edgar","filing":"0001373604-24-000022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000137360424000022/form4.xml","form_type":"4"}},{"id":1561866,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.001 per share","published_at":"2024-03-25T11:05:47.000Z","date":"2024-03-20","kind":"purchase","planned":false,"acquired":true,"shares":170589,"price":2.95,"value":503237.55,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote"}],"balance_after":3654053,"source":{"system":"sec-edgar","filing":"0001373604-24-000010","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000137360424000010/form4.xml","form_type":"4"}},{"id":1568707,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"ten_percent_owner":true}}],"security":"Common Stock, par value $0.001 per share","published_at":"2024-03-19T16:19:39.000Z","date":"2024-03-18","kind":"purchase","planned":false,"acquired":true,"shares":113777,"price":3.01,"value":342468.77,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.New Footnote"}],"balance_after":3483464,"source":{"system":"sec-edgar","filing":"0001373604-24-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000137360424000006/form4.xml","form_type":"4"}},{"id":2062723,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-06T01:03:17.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":1250000,"price":4,"value":5000000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"This form was filed to correct the transaction date to 1/3/2023."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1767774,"source":{"system":"sec-edgar","filing":"0001567619-23-000570","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000156761923000570/doc1.xml","form_type":"4/A","original_submission_date":"2023-01-04"}},{"id":2067751,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T00:49:33.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":1250000,"price":4,"value":5000000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":1767774,"source":{"system":"sec-edgar","filing":"0001567619-23-000371","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000156761923000371/doc1.xml","form_type":"4"}},{"id":2074218,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-30T22:42:56.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":20000,"price":4.04,"value":80800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at $4.04. Full information regarding the number of shares sold can be furnished to the SEC staff upon request."}],"balance_after":230000,"source":{"system":"sec-edgar","filing":"0001567619-22-022154","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000156761922022154/doc1.xml","form_type":"4"}},{"id":2074981,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-29T23:18:00.000Z","date":"2022-12-29","kind":"sale","acquired":false,"shares":19843,"price":4.04,"value":80165.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at $4.06. Full information regarding the number of shares sold can be furnished to the SEC staff upon request."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0001567619-22-022103","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000156761922022103/doc1.xml","form_type":"4"}},{"id":2074980,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-29T23:18:00.000Z","date":"2022-12-28","kind":"sale","acquired":false,"shares":157,"price":4.04,"value":634.28,"ownership":{"direct":true},"balance_after":269843,"source":{"system":"sec-edgar","filing":"0001567619-22-022103","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000156761922022103/doc1.xml","form_type":"4"}},{"id":2075203,"issuer":{"id":7624,"kind":"organization","name":"RETRACTABLE TECHNOLOGIES INC"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-29T22:43:49.000Z","date":"2022-12-29","kind":"sale","acquired":false,"shares":3000000,"price":1.6,"value":4800000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in one negotiated transaction at $1.60."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":688575,"source":{"system":"sec-edgar","filing":"0001567619-22-022102","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946563/000156761922022102/doc1.xml","form_type":"4"}},{"id":2076109,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T14:34:50.000Z","date":"2022-12-23","kind":"sale","acquired":false,"shares":48922,"price":4.06,"value":198623.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at $4.06. Full information regarding the number of shares sold can be furnished to the SEC staff upon request."}],"balance_after":270000,"source":{"system":"sec-edgar","filing":"0001567619-22-022014","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000156761922022014/doc1.xml","form_type":"4"}},{"id":2076108,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-27T14:34:50.000Z","date":"2022-12-22","kind":"sale","acquired":false,"shares":1078,"price":4.06,"value":4376.68,"ownership":{"direct":true},"balance_after":318922,"source":{"system":"sec-edgar","filing":"0001567619-22-022014","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000156761922022014/doc1.xml","form_type":"4"}},{"id":2078543,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-21T22:49:18.000Z","date":"2022-12-21","kind":"purchase","acquired":true,"shares":120099,"price":0.4,"value":48039.6,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":6160570,"source":{"system":"sec-edgar","filing":"0001567619-22-021933","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000156761922021933/doc1.xml","form_type":"4"}},{"id":2078542,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-21T22:49:18.000Z","date":"2022-12-20","kind":"purchase","acquired":true,"shares":50122,"price":0.3791,"value":19001.2502,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.375 to $0.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":6040471,"source":{"system":"sec-edgar","filing":"0001567619-22-021933","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000156761922021933/doc1.xml","form_type":"4"}},{"id":2078541,"issuer":{"id":115177,"kind":"organization","name":"Metacrine, Inc.","symbol":"MTCR"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-21T22:49:18.000Z","date":"2022-12-19","kind":"purchase","acquired":true,"shares":101384,"price":0.4,"value":40553.6,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were purchased in multiple transactions at $0.40. Full information regarding the number of shares purchased can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":5990349,"source":{"system":"sec-edgar","filing":"0001567619-22-021933","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373603/000156761922021933/doc1.xml","form_type":"4"}},{"id":2098978,"issuer":{"id":7805,"kind":"organization","name":"ASTROTECH Corp","symbol":"ASTC"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-02T23:38:33.000Z","date":"2022-12-02","kind":"purchase","acquired":true,"shares":190971,"price":0.3435,"value":65598.5385,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P.(1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions between $0.3349 and $0.35. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"1. BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":6612311,"source":{"system":"sec-edgar","filing":"0001567619-22-021236","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001907/000156761922021236/doc1.xml","form_type":"4"}},{"id":2101793,"issuer":{"id":7624,"kind":"organization","name":"RETRACTABLE TECHNOLOGIES INC"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-01T01:14:40.000Z","date":"2022-11-29","kind":"sale","acquired":false,"shares":250000,"price":2,"value":500000.0,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3688575,"source":{"system":"sec-edgar","filing":"0001567619-22-021070","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/946563/000156761922021070/doc1.xml","form_type":"4"}},{"id":2101792,"issuer":{"id":7624,"kind":"organization","name":"RETRACTABLE TECHNOLOGIES INC"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-01T01:14:40.000Z","date":"2022-11-28","kind":"sale","acquired":false,"shares":2400,"price":2.3017,"value":5524.08,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.30 to $2.31. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":3918575,"source":{"system":"sec-edgar","filing":"0001567619-22-021070","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/946563/000156761922021070/doc1.xml","form_type":"4"}},{"id":2104580,"issuer":{"id":7805,"kind":"organization","name":"ASTROTECH Corp","symbol":"ASTC"},"owners":[{"id":46438,"kind":"person","name":"Leonard Braden Michael","position":1,"cik":"0001373603","reported_name":"Leonard Braden Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-25T16:02:38.000Z","date":"2022-11-23","kind":"purchase","acquired":true,"shares":75000,"price":0.3287,"value":24652.5,"ownership":{"direct":false,"nature":"Holding of BML Investment Partners, L.P.(1)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions between $0.3221 and $0.347. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"1. BML Capital Management, LLC (\"BML Capital\") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the \"Fund\"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":6421340,"source":{"system":"sec-edgar","filing":"0001567619-22-020878","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1001907/000156761922020878/doc1.xml","form_type":"4"}}],"next_cursor":"2022-11-25T16:02:38.000000Z,2104580"}